KALA SELL SELL SELL++++++OMG this garbage has been run up too fast by the pump n dump crowd! Look at KTRA, this is what happens to these up then back down to reality. Money losing FDA blah blah overvalued
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−16.254EUR
−38.23 MEUR
2.42 M
About KALA BIO, Inc.
Sector
CEO
Mark T. Iwicki
Headquarters
Arlington
Website
Employees (FY)
43
Founded
2009
FIGI
BBG00H90SS37
KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
KALA New Drug on the Street Hi Traders
We can't say much here!
As always history has shown us when a new drug goes on the market we have 3 scenarios:
1 we're going up (green path)
2 the medicine is not good we are going down (red path)
3 we don't know what the medicine is like until many people take it let's go sideways (pur
Kala Pharma 450% gain incomingBanks has a lot of Long Hedges Open on these tickers, they have been overall short the last 1,5 years.
Now in March they began to close their first Long Hedge position.
Question right now is, did they build up big position yet for the longside, or they just sold their long Hedge and want price to go
KALA Levels + Short InfoShort squeeze stocks have become a favorite recently. KALA has started getting wrapped into the conversation. Looking at details from sites like FinViz, short float is around 20% meanwhile the float itself shows to be around 42 million shares. Plotting some levels, you'll notice that KALA is still i
KALA Technical Analysis 🧙Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have
recent higher lows illustrate sign of accumulationMost recent notes from BoA, "KALA provided updates on the preclinical programs, such as tyrosine kinase inhibitor program in retinal diseases (e.g. wet AMD), selective glucocorticoid receptor modulators (SEGRMs) and novel steroids. Mgmt. believes there is high unmet need in areas, such as wet age-re
KALA Part 2?Looks like history will repeat here. Perfect cup and handle on the daily first go around.. Next 2 months should remain flat then into a move up pending any news.
it might be time to go liquid then get back inIt seems as though its selling off till earnings......i might get back in , if earnings lookout is +
kala Pharmaceuticals Stock AnalysisKala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease
-- FDA Sets PDUFA Goal Date of October 30, 202
The idea is to go long hoping to get the good news from the FDA.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange KALA PHARMACEUTICALS INC. stocks are traded under the ticker 27F0.
KALA PHARMACEUTICALS INC. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
27F0 earnings for the last quarter are −3.89 EUR per share, whereas the estimation was −2.68 EUR resulting in a −45.33% surprise. The estimated earnings for the next quarter are −2.64 EUR per share. See more details about KALA PHARMACEUTICALS INC. earnings.
KALA PHARMACEUTICALS INC. revenue for the last quarter amounts to 0 EUR despite the estimated figure of 0 EUR. In the next quarter revenue is expected to reach 0 EUR.
Yes, you can track KALA PHARMACEUTICALS INC. financials in yearly and quarterly reports right on TradingView.
27F0 net income for the last quarter is −7.82 M EUR, while the quarter before that showed −8.23 M EUR of net income which accounts for 5.07% change. Track more KALA PHARMACEUTICALS INC. financial stats to get the full picture.
No, 27F0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 27F0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KALA PHARMACEUTICALS INC. stock right from TradingView charts — choose your broker and connect to your account.
27F0 reached its all-time high on Jan 2, 2023 with the price of 54.200 EUR, and its all-time low was 3.325 EUR and was reached on Dec 23, 2022. View more price dynamics on 27F0 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 15, 2024, the company has 43.00 employees. See our rating of the largest employees — is KALA PHARMACEUTICALS INC. on this list?
We've gathered analysts' opinions on KALA PHARMACEUTICALS INC. future price: according to them, 27F0 price has a max estimate of 19.55 EUR and a min estimate of 13.96 EUR. Watch 27F0 chart and read a more detailed KALA PHARMACEUTICALS INC. stock forecast: see what analysts think of KALA PHARMACEUTICALS INC. and suggest that you do with its stocks.